Scientific Advisory Board
Jeffrey L. Cummings, MD, ScD, is Founding Director, Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio. He is Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He also serves as Principal Investigator/Director of the NIH/NIGMS-funded Center for Neurodegeneration and Translational Neuroscience. Dr. Cummings is a recognized world leader in Alzheimer’s researcher and clinical trials. His many honors include the Henderson Award of the American Geriatrics Society (2006), the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008), and the Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017). In 2010, he was honored by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award. In 2018, he received the Leadership and Achievement Award by the International Society of CNS Drug Development and the Bengt Winblad Lifetime Achievement Award from the national Alzheimer’s Association. He was featured in the Gentleman’s Quarterly (June 2009) as a “Rock Star of Science.”
Jeffery L. Cummings, MD, ScD
Dr. Reiman is Executive Director of the Banner Alzheimer’s Institute, Chief Executive Officer of Banner Research, Professor of Psychiatry at the University of Arizona, University Professor of Neuroscience at Arizona State University, Clinical Director of Neurogenomics at the Translational Genomics Research Institute (TGen), and Director of the Arizona Alzheimer’s Consortium. Following his Psychiatry Training at Duke and Washington University, and launched his career in brain imaging research under Marcus Raichle at Washington University in St. Louis. He is a widely recognized leader in brain imaging, brain mapping, genomics, early detection and tracking of Alzheimer’s disease (AD), and the accelerated evaluation of Alzheimer’s prevention therapies. He and his Banner Alzheimer’s Institute colleagues established the Alzheimer’s Prevention Initiative (API) to launch a new era in Alzheimer’s prevention research. Dr. Reiman is an author of more than 400 publications, a principal investigator of six current NIH grants, and a member of the National Advisory Council on Aging (NIA Council). He is a recipient of the Potamkin Prize for his pioneering contributions to the study of preclinical AD and the accelerated evaluation of AD prevention therapies.
Lon Schneider, MD, serves as Director of the USC National Institute on Aging Alzheimer’s Disease Research Center clinical core and the USC State of California Alzheimer’s Disease Center. His advisory roles have included senior scientific advisor at the NIMH, on the American Psychiatric Association Committee for Practice Guidelines in Alzheimer’s and Other Dementia, the World Federation of Societies of Biological Psychiatry Task Force on Dementia. He holds a master’s degree in biometry and epidemiology and is a widely sought expert in clinical trials methods and drug development. His work involves development with novel neuroregenerative disese therapeutics, the science of outcomes assessment, and approaches to modeling and clinical trials simulations. He is an associate editor or editorial board member of several publications, including the Cochrane Dementia and Cognitive Improvement Group, Current Alzheimer Research, BMC-Psychiatry, Alzheimer’s & Dementia, The Lancet Neurology, and Clinical Neuropharmacology among others. He serves as editor-in-chief of Alzheimer’s & Dementia: Translational Research and Clinical Interventions; and has authored numerous papers and chapters.